Profile
Lis is a trusted corporate lawyer with a reputation for combining sharp legal expertise with a deep understanding of business strategy. She advises listed and private companies, multinationals, and not-for-profit organisations on governance, structure, operations, and growth. Her clients value her ability to build enduring relationships and immerse herself in their culture, ensuring advice that is timely, practical, and aligned with their vision.
At the strategic level, Lis partners with boards and senior executives on high-impact transactions — from capital raisings and restructures to strategic collaborations and mergers & acquisitions. Her extensive experience and pragmatic insights are particularly sought after by growing organisations navigating complex projects.
Lis also helps organisations strengthen governance frameworks, making them fit for purpose and future-ready. She brings emotional intelligence to sensitive matters such as member approvals and conflicts of interest, drawing on her credentials as a graduate of the Australian Institute of Company Directors. For listed entities, she provides clear, actionable guidance on continuous disclosure obligations.
Operationally, Lis champions a practical approach to embedding compliance in everyday operations. She trains boards and managers on key legal duties, designs contract review frameworks aligned with risk appetite, and negotiates complex agreements with precision.
Her deep understanding of the Life Sciences and Healthcare sector is reflected in her leadership roles:
- Co-Chair, Piper Alderman Life Sciences and Healthcare focus group
- Non-Executive Director, Immutep Ltd (ASX: IMM; NASDAQ: IMMP)
- Chair, AusBiotech NSW State Committee
A regular speaker at AusBiotech conferences, ANDHealth workshops, and BioShares masterclasses, Lis is a natural connector, fostering collaboration and strengthening Australia’s life sciences ecosystem.
Expertise
Recognition
“Lis has a high profile and provides timely and helpful guidance on commercial and corporate matters.”
Chambers Asia Pacific Guide: Life Sciences, 2025 edition
“Lis provides amazing advice and remains knowledgeable on current topics and trends.”
Chambers Asia Pacific Guide: Life Sciences, 2025 edition
“Lis is a wonderful asset to the Australian life sciences community, with a very service-oriented approach to her clients.”
Chambers Asia Pacific Guide: Life Sciences, 2023 edition
“She has always been my point person and is always readily available to talk through any prickly topics. And the speed to provide the advice is second to none. Very much appreciated in a competitive market.”
Chambers Asia Pacific Guide: Life Sciences, 2023 edition
“Lis Boyce is very commercial, personally engaged, quick to call in further expertise from within the firm where required. Lis has been actively involved in our matters and has helped us resolve several difficult situations with investors relating to contract technicalities, debt and equity maturity, and conversion, adjustment of shareholdings, deal documentation.”
The Legal 500 Asia-Pacific: Corporate and M&A, 2021 edition – Testimonials
Accolades
- Chambers Asia-Pacific Guide – Life Sciences – Band 4 since 2021 edition
- Best Lawyers in Australia – Recognised for Life Sciences Practice (Sydney, AU) – since 2020 edition
- The Legal 500 Asia-Pacific – Recognised ‘Key Lawyer’ for Corporate and M&A – 2021 to 2024 editions
Recent deals and media coverage
- Top 10 Most Influential Life Sciences Lawyers in Australia 2023 Revealed – Business Today News, 29 July 2023
- Aerospace engineering company advised on Series B funding round – Lawyers Weekly, 13 September 2022
- AMSL Innovations Pty Ltd’s Series B Equity Funding Round – Global Legal Chronicle, 7 September 2022
- Lindsay Dynan merges with Hatch – Lawyers Weekly, 27 January 2021
- Piper Alderman recruits health and life sciences partner – Lawyers Weekly, 31 January 2021
Memberships
- Graduate, Australian Institute of Company Directors
- Fellow, Governance Institute of Australia
- Senior Fellow, Financial Services Institute of Australasia
Insights
17 June 2025
Time to brush up on continuous disclosure obligations – ASX to introduce a “close review...
Read More29 May 2025
Schemes of Arrangement – What not to do as a substantial shareholder. Unacceptable Circumstances
Read More11 March 2025
To name or not to name? ASX revises its approach to continuous disclosure obligations for...
Read More28 October 2024
Webinar Q&As: Navigating the New Australian Anti-Bribery Laws | What You Need to Know
Read More25 October 2024
Webinar Q&As: 2024 ‘Clause & Effect’ Series | Navigating Contractual Risks: Limitation of Liability, Warranties,...
Read More21 August 2024
Corporate takeovers done lawfully: A guide for unlisted public companies in growth mode
Read More24 March 2023
Webinar Q&As: 2023 ‘Beat the Clock’ Series: Professional skills | The contract review toolkit
Read More13 December 2022
Webinar Q&As: Crisis Management – When it hits the fan… responding to a crisis
Read More15 August 2022
ESG Reporting for Life Sciences Companies (as if saving lives wasn’t enough….)
Read More04 August 2022
Lexology Getting the Deal Through – Data Protection and Privacy, 2023 Edition
Read More14 February 2022
Temporary measures made permanent: Corporations Amendment (Meetings and Documents) Bill 2021 passed by the Senate
Read More14 February 2022
Goodbye Wet-ink – Hello, Electronic Signing: Revisions to the Corporations Act 2001
Read More30 September 2021
COVID-19 testing at home: new regulation to allow rapid antigen self-tests
Read More30 August 2021
COVID-19 rapid antigen tests: complying with advertising and supply requirements
Read More01 June 2020
What happens when a charity’s purpose can’t be amended? Lessons from Bushfire Fundraising and the...
Read More09 April 2020
COVID-19 Stimulus Measures – How is the Federal Government assisting Not-for-Profits?
Read More07 April 2020
Members’ meetings in the Age of COVID-19 – Can members’ meetings of charities that are...
Read MoreCase Studies
21 January 2022
